PTC857

DRUG2 trials

Sponsors

PTC Therapeutics Inc., PTC Therapeutics

Conditions

Amyotrophic Lateral Sclerosis

Phase 2

Study to Assess the Effects of PTC857 Treatment in Participants With Amyotrophic Lateral Sclerosis ALS

TerminatedNCT05349721

PTC TherapeuticsAmyotrophic Lateral Sclerosis

Start: 2022-05-15End: 2025-01-30Updated: 2025-08-01

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Assess the Efficacy, Safety, Tolerability, PK, and Biomarker Effects of PTC857 in Adult Subjects With Amyotrophic Lateral Sclerosis (CARDINALS)

CompletedCTIS2023-510317-26-00

PTC Therapeutics Inc.Amyotrophic Lateral Sclerosis

Start: 2023-02-07End: 2024-11-26Target: 242Updated: 2024-12-10

Related Papers

CARDINALS: A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Utreloxastat (PTC857) in Patients with Amyotrophic Lateral Sclerosis (P5-11.010)

Neurology2024-04-09